E+H has advised PAI Partners on the acquisition of VAMED Group's rehabilitation business from Fresenius. Schoenherr, working with Latham & Watkins, advised the sellers. Reportedly, Willkie Farr & Gallagher, Novacos, Baer & Karrer, KNPZ Rechtsanwaelte, and Havel & Partners advised on the deal as well.
Reverse Due Diligence of Deal Partners
Historically and statistically, most joint ventures and business combinations have short and difficult lives. Lawyers can assist with preparation and negotiation of best of class, workable and practical corporate and legal structures and agreements. But only the parties, the would-be partners, can make the combined business work and succeed.
DLA Piper Advises Brand24 and Shareholders on 57.6% Sale to Semrush
DLA Piper has advised Brand24 and its shareholders (including Laeq, Unfold.vc, and Michal Sadowski and Piotr Wierzejewski funds) on the sale of a 57.6% stake to Semrush.
ODI Law and Senica & Partners Advise on Katera's Acquisition of Majority Stake in Nama
ODI Law has advised German Katera Beteiligungs-Verwaltungsgesellschaft P11 mbH on its acquisition of an 87,58% shareholding in Nama from Zavarovalnica Triglav and Generali. Senica & Partners advised Zavarovalnica Triglav on the deal.
Schoenherr Advises ITgma on Sale to Modirum
Schoenherr has advised the owners of ITgma on the sale of a majority ownership stake to Modirum.
Key Takeaways From Year One of the Slovak FDI regime
The first comprehensive Slovak foreign direct investment (FDI) screening regime entered into force on 1 March 2023. Now that the first year of this new FDI regime is behind us, below we summarise the key takeaways based on our practical experience with this law.
CMS Advises EBRD on EUR 22 Million Loan to Farmak Group for Polish Pharma Acquisition and IT Upgrades
CMS, working with Harneys Cyprus, has advised the European Bank for Reconstruction and Development on a EUR 22 million loan to the Cyprus-based Farmak Group and Ukraine's JSC Farmak for the acquisition of Poland's Symphar and the upgrade of JSC Farmak's IT systems.